Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment

References

• Choo EJ, Chambers HF. Treatment of methicillin-resistant staphylococcus aureus bacteremia. Infect Chemother. 2016;48(4):267–273. doi:10.3947/ic.2016.48.4.267
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864. doi:10.1093/ajhp/zxaa036
   PubMed Web of Science ®Google Scholar
• Yan X, Tao X, He L, Cui Z, Zhang J. Increasing resistance in multiresistant methicillin-resistant Staphylococcus aureus clones isolated from a Chinese hospital over a 5-year period. Microb Drug Resist. 2011;17(2):235–239. doi:10.1089/mdr.2010.0029
   PubMed Web of Science ®Google Scholar
• Marlowe KF, Chicella MF, Claridge TE, Pittman SW. An assessment of vancomycin pharmacokinetic variability in pediatric cardiology patients. J Pediatr Pharmacol Ther. 2003;8(2):132–136. doi:10.5863/1551-6776-8.2.132
   PubMedGoogle Scholar
• Revilla N, Martín-Suárez A, Pérez MP, González FM, Fernández de Gatta Mdel M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol. 2010;70(2):201–212. doi:10.1111/j.1365-2125.2010.03679.x
   PubMed Web of Science ®Google Scholar
• Stockmann C, Hersh AL, Roberts JK, et al. Predictive performance of a vancomycin population pharmacokinetic model in neonates. Infect Dis Ther. 2015;4(2):187–198. doi:10.1007/s40121-015-0067-9
   PubMedGoogle Scholar
• Aljutayli A, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, part I: in adults. Clin Pharmacokinet. 2020;59(6):671–698. doi:10.1007/s40262-020-00866-2
   PubMed Web of Science ®Google Scholar
• Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;55(12):5475–5479. doi:10.1128/aac.00168-11
   PubMed Web of Science ®Google Scholar
• Kim JY, Yee J, Yoon HY, Han JM, Gwak HS. Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:3977–3989. doi:10.1111/bcp.15429
   PubMed Web of Science ®Google Scholar
• Sharma M, Braekevelt K, Kale-Pradhan P, Szpunar S, Khatib R. Are blacks at higher risk for vancomycin-related acute kidney injury? J Pharm Pract. 2020;33(5):592–597. doi:10.1177/0897190018800093
   PubMed Web of Science ®Google Scholar
• Olafuyi O, Parekh N, Wright J, Koenig J. Inter‐ethnic differences in pharmacokinetics—is there more that unites than divides? Pharmacol Res Perspect. 2021;9(6):e00890. doi:10.1002/prp2.890
   PubMed Web of Science ®Google Scholar
• Zaric RZ, Milovanovic J, Rosic N, et al. Pharmacokinetics of vancomycin in patients with different renal function levels. Open Med. 2018;13:512–519. doi:10.1515/med-2018-0068
   Web of Science ®Google Scholar
• Bjornsson TD. Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet. 1979;4(3):200–222. doi:10.2165/00003088-197904030-00003
   PubMed Web of Science ®Google Scholar
• Schobben F, van der Kleijn E. Drug determinations in body fluids by the enzyme multiplied immunoassay technique (EMIT®). Eur J Drug Metab Pharmacokinet. 1977;2(4):185–189. doi:10.1007/BF03189304
   Google Scholar
• Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221–234. doi:10.2165/00003088-200746030-00003
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Department of Health and Human Services. Center for drug evaluation and research. Population pharmacokinetics: guidance for industry. Available from: https://www.fda.gov/media/71364/download. Accessed March 27, 2021.
   Google Scholar
• Chu Y, Luo Y, Ji S, Jiang M, Zhou B. Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance. J Infect Public Health. 2019;13(1):68–74. doi:10.1016/j.jiph.2019.06.016
   PubMed Web of Science ®Google Scholar
• Jing L, Liu -T-T, Guo Q, Chen M, Lu -J-J, C-l L. Development and comparison of population pharmacokinetic models of vancomycin in neurosurgical patients based on two different renal function markers. JJ Clin Pharm Ther. 2019;45(1):88–96. doi:10.1111/jcpt.13029
   PubMed Web of Science ®Google Scholar
• Kovacevic T, Miljkovic B, Kovacevic P, et al. Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients. J Crit Care. 2020;55:116–121. doi:10.1016/j.jcrc.2019.10.012
   PubMed Web of Science ®Google Scholar
• Liu TT, Pang HM, Jing L, et al. A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function. J Pharm Pharmacol. 2019;71(6):945–955. doi:10.1111/jphp.13071
   PubMed Web of Science ®Google Scholar
• J-J L, Chen M, C-L L, et al. A population pharmacokinetics model for vancomycin dosage optimization based on serum cystatin C. Eur J Drug Metab Pharmacokinet. 2020;45(4):535–546. doi:10.1007/s13318-020-00621-9
   PubMed Web of Science ®Google Scholar
• Ma KF, Liu YX, Jiao Z, et al. Population pharmacokinetics of vancomycin in kidney transplant recipients: model building and parameter optimization. Front Pharmacol. 2020;11:563967. doi:10.3389/fphar.2020.563967
   PubMed Web of Science ®Google Scholar
• Kim DJ, Lee DH, Ahn S, et al. A new population pharmacokinetic model for vancomycin in patients with variable renal function: therapeutic drug monitoring based on extended covariate model using CKD-EPI estimation. J Clin Pharm Ther. 2019;44(5):750–759. doi:10.1111/jcpt.12995
   PubMed Web of Science ®Google Scholar
• Yasuhara M, Iga T, Zenda H, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20(2):139–148. doi:10.1097/00007691-199804000-00003
   PubMed Web of Science ®Google Scholar
• Chung J-Y, Jin S-J, Yoon J-H, Song Y-G. Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci. 2013;28(1):48–54. doi:10.3346/jkms.2013.28.1.48
   PubMed Web of Science ®Google Scholar
• Leroux S, Biran V, van den Anker J, et al. Serum creatinine and serum cystatin c are both relevant renal markers to estimate vancomycin clearance in critically ill neonates. Front Pharmacol. 2021;12:634686. doi:10.3389/fphar.2021.634686
   PubMed Web of Science ®Google Scholar
• Mangin O, Urien S, Mainardi JL, Fagon JY, Faisy C. Vancomycin pharmacokinetic and pharmacodynamic models for critically ill patients with post-sternotomy mediastinitis. Clin Pharmacokinet. 2014;53(9):849–861. doi:10.1007/s40262-014-0164-z
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Alsultan AS, Alqattan HM, Eldemerdash A, Albacker TB. Population pharmacokinetic model for vancomycin used in open heart surgery: model-based evaluation of standard dosing regimens. Antimicrob Agents Chemother. 2018;62:7.
   Web of Science ®Google Scholar
• Jalusic KO, Hempel G, Arnemann PH, et al. Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis. Br J Clin Pharmacol. 2021;87(6):2502–2510. doi:10.1111/bcp.14657
   PubMedGoogle Scholar
• Okada A, Kariya M, Irie K, et al. Population pharmacokinetics of vancomycin in patients undergoing allogeneic hematopoietic stem-cell transplantation. J Clin Pharmacol. 2018;58(9):1140–1149. doi:10.1002/jcph.1106
   PubMed Web of Science ®Google Scholar
• Vu DH, Nguyen DA, Delattre IK, et al. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: population pharmacokinetic modelling and simulations for improved dosing schemes. Int J Antimicrob Agents. 2019;54(6):702–708. doi:10.1016/j.ijantimicag.2019.09.018
   PubMed Web of Science ®Google Scholar
• Garreau R, Falquet B, Mioux L, et al. Population pharmacokinetics and dosing simulation of vancomycin administered by continuous injection in critically ill patient. Antibiotics. 2021;10(10). doi:10.3390/antibiotics10101228
   Google Scholar